Co-Diagnostics (NASDAQ:CODX – Get Free Report) and Establishment Labs (NASDAQ:ESTA – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Co-Diagnostics and Establishment Labs, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Co-Diagnostics | 1 | 2 | 1 | 0 | 2.00 |
| Establishment Labs | 1 | 1 | 6 | 0 | 2.63 |
Co-Diagnostics presently has a consensus target price of $55.00, suggesting a potential upside of 2,086.01%. Establishment Labs has a consensus target price of $78.86, suggesting a potential upside of 3.45%. Given Co-Diagnostics’ higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than Establishment Labs.
Volatility and Risk
Profitability
This table compares Co-Diagnostics and Establishment Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Co-Diagnostics | -6,347.34% | -70.26% | -61.19% |
| Establishment Labs | -43.45% | -235.45% | -22.83% |
Valuation and Earnings
This table compares Co-Diagnostics and Establishment Labs”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Co-Diagnostics | $507,892.00 | 11.18 | -$37.64 million | ($29.73) | -0.08 |
| Establishment Labs | $166.02 million | 13.34 | -$84.60 million | ($2.84) | -26.84 |
Co-Diagnostics has higher earnings, but lower revenue than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 5.4% of Co-Diagnostics shares are owned by company insiders. Comparatively, 11.1% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Establishment Labs beats Co-Diagnostics on 9 of the 14 factors compared between the two stocks.
About Co-Diagnostics
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
About Establishment Labs
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
